INS and type 1 diabetes mellitus: Finally, the Primary Oral Insulin Trial (POInT) [8], which started recruitment in 2018, has enrolled 1050 children with a high polygenic risk score for type 1 diabetes across Belgium, Germany, Poland, Sweden and the UK.